SCHEMBL3352542

SCHEMBL3352542

Cc1ccccc1CNCCCN(O)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.58
HPGD P15428 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KMT2A Q03164 2/20 0.43
HTT P42858 1/20 0.43
GAA P10253 1/20 0.43
CA12 O43570 4/20 0.41
CA2 P00918 4/20 0.41
CA9 Q16790 4/20 0.41
MEN1 O00255 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SCN8A Q9UQD0 2/20 0.41
TP53 P04637 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL3909886 0.96 CHRM2 (0.54) CHRM2HPGDALDH1A1KMT2AHTT
Toluene SCHEMBL3916489 0.79 CHRM2 (0.51) CHRM2HPGDKMT2AMEN1KDM4E
SCHEMBL11638296 0.79 CHRM2 (0.69) CHRM2HTTCA12CA2CA9
SCHEMBL5769664 0.78 CHRM2 (0.73) CHRM2ALDH1A1KMT2AHTTCA12
Hydrochloric Acid SCHEMBL8891860 0.78 CHRM2 (0.63) CHRM2HPGDALDH1A1KMT2AHTT
SCHEMBL3356515 0.77 HDAC3 (0.44) CHRM2KMT2ATSHRTP53
SCHEMBL3356470 0.77 CHRM2 (0.56) CHRM2HPGDKMT2ACA12CA2
Toluene SCHEMBL3904509 0.75 REN (0.47) ALDH1A1KMT2AHTTMEN1KDM4E
SCHEMBL3210618 0.75 CHRM2 (0.59) CHRM2HPGDALDH1A1KMT2AHTT
SCHEMBL10925708 0.75 CHRM2 (0.80) CHRM2ALDH1A1CA12CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CHRM2 876/4885HPGD 1390/4885ALDH1A1 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.